Neurology and Neurosurgery
Below, please find links to all of the clinical trials involving neurology and/or neurosurgery. The studies include a multitude of information, including (but not limited to) the study’s purpose, benefits for participating, and financial incentive information. If you have any questions, please contact the individual outlined at the end of each trial summary.
Please visit the Neurology & Neurosurgery service webpage at the Veterinary Medical Teaching Hospital (VMTH) if you would like to learn more about the amazing things that our neurologists can do for you and your animal. More information about the Neurology & Neurosurgery service research can be found here.
Title: MHC Haplotyping of cats with Acquired Myasthenia Gravis
Purpose of Study: Acquired myasthenia gravis is an immune mediated disease. In people, there is an association between genes (HLA DR3) and the myasthenia gravis. If the same is true in cats, it may allow us to identify cats at risk before the development of disease and develop new treatments. The purpose of this study is to determine if cats with acquired myasthenia gravis have a similar genes (MHC haplotype). We will use DNA collected from blood cells to do the genetic analysis.
Contact: Contact Dr. Vernau at (530) 304-9450 or firstname.lastname@example.org.
Participation Requirements: Cats with a confirmed diagnosis of acquired Myasthenia Gravis.
Initial Evaluation for Participation: None.
Procedures: The only procedure involved is for the owner or referring veterinarian to submit a blood sample (at least 2 mls) in a small EDTA tubes.
Benefits: There is no direct benefit of this study for you or your cat; however, the information may allow us to identify cats that are at risk and develop new treatments.
Owner Responsibilities: The owner or referring veterinarian only needs to send in a blood sample that has been collected in a small EDTA tube by over-night FedEx, sent Monday to Thursday.
Title: Phosphorylated heavy chain neurofilament as a biomarker in dogs with intervertebral disc herniation
Purpose: Intervertebral disc herniation commonly results in compression and bruising of the spinal cord in dogs, and is commonly seen in dachshunds. Surgery to remove disc material compressing the spinal cord leads to recovery of function in almost all dachshunds that still have pain sensation in their pelvic limbs but the outcome is much more variable when pain sensation has already been lost. Additionally, about 10% of the most severely affected dogs develop a fatal destruction of their spinal cord (myelomalacia) regardless of our attempts to intervene. For dogs that have lost pain sensation, we know that approximately half of them, if surgery is performed promptly, will recover the ability to walk on their own, but we do not have a good means of predicting which dogs will improve following surgery, and how quickly or completely this will happen. The purpose of this study is to assess the utility of pNF-H, a biomarker released from damaged axons of the spinal cord into the bloodstream, to predict return of function following surgery in dachshunds without pain sensation in their hind limbs due to disc herniation.
Participation Requirements: Dachshunds with spinal cord injury from intervertebral disc herniation in the thoracolumbar region both with and without pain sensation in the hindlimbs
Initial Evaluation for Participation: Before your dog begins the study, your dog will need to have a blood sample collected, physical and neurological examination, MRI or CT of the thoracolumbar spine to verify disc herniation, and surgical removal of herniated disc material to decompress the spinal cord.
Procedures: If your dog is determined to be eligible for the study and you choose to enroll them, your dog will receive routine diagnostics and treatment as well as the following as part of the study:
- Blood collection every 12 hours following surgery for up to 5 days and then at the 2-week postoperative recheck visit
- Neurologic examination at 2-weeks post-surgery and then again at 6-weeks and 3-months post-surgery (for dogs without hindlimb sensation prior to surgery)
Benefits: The study will cover the follow-up examinations and bloodwork while at the VMTH and at the 2-week follow-up (dogs with sensation prior to surgery). For dogs without sensation prior to surgery, an additional 6-week and 3-month follow-up examination will be covered.
While there is no direct medical or financial benefit to your pet’s initial care, this study may result in an ability for us to better predict outcome for dogs in a similar situation as yours in the future.
Owner Responsibilities: We expect your participation in this trial will last for up to 3 months. If you wish to have your pet participate in this study, you will be responsible for covering all routine diagnostic procedures and treatment, bringing your dog to the VMTH, keeping all scheduled appointments, alerting the study veterinarians if your dog regains the ability to walk without assistance while at home between those visits.
Printable Flyer (PDF)
Title: MPR nanoparticles to define brain tumor margins in canine primary brain tumors: Phase I pilot study
Purpose: This clinical trial is being done to investigate whether small particles called nanoporhphyrins can be used to better visualize tumors during surgery and potentially to see if they will be a useful method to deliver drugs into brain tumors for treatment.
Contact: Contact Lisa Winn (Neurology Scheduling Coordinator) at email@example.com or (530) 752-1393 and follow the prompts for Neurology/Neurosurgery
Participation Requirements: Dogs provisionally diagnosed with a brain tumor
Procedures: If you agree to let your dog participate in this study, the following will happen:
- Administration of nanoparticles approximately 12-36 hours, collection of blood and urine for analysis prior to surgery
- Brain surgery to remove the tumor (standard therapy for brain tumors)
- Blood collection 1-week post-administration of nanoparticles
Benefits: The study will provide up to $5,000 credit towards your dog’s treatment.
We hope that this technique will help us to better visualize the tumor on MRI, allowing for better planning of the surgery. Information obtained from your dog's treatment may help to further develop this type of treatment for both dogs and humans and could improve the treatment in both species in the future.
Owner Responsibilities: If you allow your dog to participate in this study, you will be responsible for keeping all scheduled appointments, and covering the costs of your dog’s standard treatment during the clinical trial and any complications arising from that treatment or from the clinical trial procedures.
Printable Flyer (PDF)
Title: Genome wide association in canine primary brain tumors
Purpose: Brachycephaly, a trait characterized by a short muzzle and wide head, is associated with brain tumors and respiratory problems. This trait is found in several breeds, including Boxers, Bulldogs, and Boston Terriers We are attempting to uncover the genetic cause for brachycephaly in dogs while looking for genes linked to brachycephaly that may increase the risk of developing a brain tumor.
Contact: For information, please email Dr. Dickinson at firstname.lastname@example.org.
Initial Evaluation for Participation: Examination by Dr. Dickinson
Procedures: We are collecting DNA from dogs known or suspected to have a brain tumor. For information, please contact Dr. Dickinson (email@example.com).
Benefits: There is no direct benefit to you or your dog; however, identification of these genes may allow for:
- Selective breeding to reduce the frequency of brain tumors in brachycephalic dogs
- Possible new therapies targeting defective genes
For dogs with confirmed tumors, we can discuss treatment options and available clinical trials that could help treat your dog's tumor.
Owner Responsibilities: Please contact Dr. Dickinson (firstname.lastname@example.org)
Title: MHC Haplotyping of dogs with Acquired Myasthenia Gravis
Purpose of Study: Acquired myasthenia gravis is an immune mediated disease. In people, there is an association between genes (HLA DR3) and the myasthenia gravis. If the same is true in dogs, it may allow us to identify dogs at risk before the development of disease, and it may allow us to develop new treatments. The purpose of this study is to determine if dogs with acquired myasthenia gravis have a similar genes (MHC haplotype). We will use DNA collected from blood cells to do the genetic analysis. The genetic analysis will be done in the UC Davis School of Veterinary Medicine.
Contact: Contact Dr. Vernau at (530) 752-1393, (530) 304-9450, or email@example.com
Participation Requirements: Dogs with a confirmed diagnosis of acquired Myasthenia Gravis.
Initial Evaluation for Participation: None.
Procedures: The only procedure involved a DNA analysis of a blood sample submitted by the owner (at least 5 mls) in 1-2 EDTA tubes.
Benefits: There is no direct benefit of this study for you or your dog; however, the information may allow us to identify dogs that are at risk and develop new treatments.
Owner Responsibilities: The owner only needs to send in a blood sample that has been collected in 1-2 tubes of EDTA by over-night FedEx, Monday to Thursday.
On Hold Until Further Notice
Title: Transplantation and Tracking of Autologous Epidermal Neural Crest Stem Cells into the Spinal Cord of Dogs with Acute Severe Spinal Cord Injury
Purpose of Study: Dogs that have suffered spinal cord trauma due to a disc herniation are typically treated with decompressive surgery and medication of various kinds. Most dogs do very well with this treatment. However, dogs that have suffered an injury severe enough to cause complete paralysis and loss of feeling to the hind legs often do not recover with conventional treatment. In these dogs, stem cell therapy may improve the ability of the dog to use his/her hind legs and/or to have control of his/her bladder. Therefore, the purpose of this study is to examine the efficacy of stem cell therapy as a potential treatment for acute severe spinal cord injuries in dogs.